stoxline Quote Chart Rank Option Currency Glossary
  
Tenaya Therapeutics, Inc. (TNYA)
0.4912  0.031 (6.64%)    04-25 16:00
Open: 0.4825
High: 0.5334
Volume: 3,285,976
  
Pre. Close: 0.4606
Low: 0.47
Market Cap: 80(M)
Technical analysis
2025-04-25 4:51:32 PM
Short term     
Mid term     
Targets 6-month :  0.69 1-year :  0.84
Resists First :  0.59 Second :  0.72
Pivot price 0.46
Supports First :  0.4 Second :  0.33
MAs MA(5) :  0.46 MA(20) :  0.49
MA(100) :  1.2 MA(250) :  2.25
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  46.7 D(3) :  36.4
RSI RSI(14): 43
52-week High :  4.96 Low :  0.39
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ TNYA ] has closed below upper band by 25.2%. Bollinger Bands are 90.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 25 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.54 - 0.54 0.54 - 0.54
Low: 0.46 - 0.47 0.47 - 0.47
Close: 0.49 - 0.49 0.49 - 0.49
Company Description

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). It is also developing TN-401, an AAV-based gene therapy that addresses genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) caused by plakophilin 2 (PKP2) gene mutations; an AAV-based gene therapy designed to deliver the dwarf open reading frame (DWORF) gene in the heart for DCM; and Reprogramming program, an AAV-based approach for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco, California.

Headline News

Thu, 24 Apr 2025
Major Breakthrough: 175-Patient ARVC Study Shows 93% Could Benefit from New Gene Therapy Treatment - Stock Titan

Mon, 31 Mar 2025
Revolutionary Gene Therapy Transforms Severe Heart Disease Patients in Landmark Trial - Stock Titan

Mon, 31 Mar 2025
Tenaya Therapeutics Announces Late Breaker Presentation - GlobeNewswire

Fri, 28 Mar 2025
Is Tenaya Therapeutics, Inc. (TNYA) the Cheapest Stock Insiders Are Buying In March? - Yahoo Finance

Tue, 25 Mar 2025
Tenaya Therapeutics, Inc. (TNYA): Among Stocks Receiving the Most Insider Love in March - Yahoo Finance

Mon, 24 Mar 2025
Tenaya Therapeutics, Inc.'s (NASDAQ:TNYA) stock price dropped 13% last week; individual investors would not be happy - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 163 (M)
Shares Float 55 (M)
Held by Insiders 1.4 (%)
Held by Institutions 106.7 (%)
Shares Short 11,220 (K)
Shares Short P.Month 13,370 (K)
Stock Financials
EPS -1.31
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.07
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -50 %
Return on Equity (ttm) -95.7 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.67
Qtrly Earnings Growth 0 %
Operating Cash Flow -91 (M)
Levered Free Cash Flow -53 (M)
Stock Valuations
PE Ratio -0.38
PEG Ratio 0
Price to Book value 0.45
Price to Sales 0
Price to Cash Flow -0.89
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android